Chemomab Therapeutics (CMMB) Return on Assets (2019 - 2025)
Chemomab Therapeutics' (CMMB) quarterly Return on Assets came in at 477.99% in Q4 2025, up 27876.0% YoY from N/an in Q4 2024, and up 48.9% on a QoQ basis from 321.01% in Q3 2025.
Chemomab Therapeutics (CMMB) Return on Assets (2019 - 2025) Analysis & Trends
Chemomab Therapeutics (CMMB) has 7 years of Return on Assets data on file, last reported at 477.99% in Q4 2025.
- Quarterly Return on Assets rose 27876.0% year-over-year to 477.99% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 477.99% (up 27876.0% YoY) and the FY2025 annual result came in at 0.01%, changed 0.0% from the prior year.
- Return on Assets rose to 477.99% in Q4 2025, from 321.01% in the prior quarter.
- In the past five years, Return on Assets ranged from a high of 477.99% in Q4 2025 to a low of 0.0% in Q1 2021.
- A 5-year average of 78.32% and a median of 0.01% in 2023 frame the typical range for Return on Assets.
- Annual changes were most pronounced in 2022 — Return on Assets changed 0 bps — and 2025, when it soared 32100 bps.
- Tracing CMMB's Return on Assets over 5 years: stood at 0.0% in 2021, then jumped by 310 bps to 0.0% in 2022, then jumped by 168 bps to 0.01% in 2023, then soared by 1873995 bps to 199.23% in 2024, then jumped by 140 bps to 477.99% in 2025.
- The last three Return on Assets figures came in at 477.99% (Q4 2025), 321.01% (Q3 2025), and 314.96% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 0.00% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 0.00% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 0.00% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 0.00% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 0.00% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 0.00% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 0.00% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 0.00% |
| 10 | Chemomab Therapeutics | 13.62 Mn | 3.25 Mn | - | 477.99% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 477.99% |
| Sep 30, 2025 | 321.01% |
| Jun 30, 2025 | 314.96% |
| Mar 31, 2025 | 253.26% |
| Dec 31, 2024 | 199.23% |
| Sep 30, 2024 | 0.01% |
| Jun 30, 2024 | 0.01% |
| Mar 31, 2024 | 0.01% |
| Dec 31, 2023 | 0.01% |
| Sep 30, 2023 | 0.01% |
| Jun 30, 2023 | 0.01% |
| Mar 31, 2023 | 0.01% |
| Dec 31, 2022 | 0.00% |
| Sep 30, 2022 | 0.00% |
| Jun 30, 2022 | 0.00% |
| Mar 31, 2022 | 0.00% |
| Dec 31, 2021 | 0.00% |
| Sep 30, 2021 | 0.00% |
| Jun 30, 2021 | 0.00% |
| Mar 31, 2021 | 0.00% |